Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBG453 in Lower Risk MDS
NCT04823624Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sabatolimab in myelodysplastic syndrome (MDS), sponsored by Massachusetts General Hospital. Started Jan 2022; status: terminated.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04823624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04823624.